Evidence map›Paper›PMID 32019267›Full record

ArticleBiomolecules2020

A Cell-Free SDKP-Conjugated Self-Assembling Peptide Hydrogel Sufficient for Improvement of Myocardial Infarction.

Saman Firoozi, Sara Pahlavan, Mohammad-Hossein Ghanian, Shahram Rabbani, Shima Tavakol, Maryam Barekat, Saeed Yakhkeshi, Elena Mahmoudi, Mansoureh Soleymani, Hossein Baharvand

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Saman FirooziDepartment of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Sara PahlavanDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
Mohammad-Hossein GhanianDepartment of Cell Engineering, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
Shahram RabbaniResearch center for advanced technologies in cardiovascular medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran 1416753955, Iran.
Shima TavakolCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Maryam BarekatDepartment of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
Saeed YakhkeshiDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
Elena MahmoudiMassachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Mansoureh SoleymaniCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Hossein BaharvandDepartment of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 1665659911, Iran.
Royan Institute · IRIran University of Medical Sciences · IRHarvard University · USTehran University of Medical Sciences · IRUniversity of Science and Culture · IR

Funding

Iran National Science Foundation 96001316Iran University of Medical Sciences -Royan Institute -
6 · The paper itself

Abstract

Biomaterials in conjunction with stem cell therapy have recently attracted attention as a new therapeutic approach for myocardial infarction (MI), with the aim to solve the delivery challenges that exist with transplanted cells. Self-assembling peptide (SAP) hydrogels comprise a promising class of synthetic biomaterials with cardiac-compatible properties such as mild gelation, injectability, rehealing ability, and potential for sequence modification. Herein, we developed an SAP hydrogel composed of a self-assembling gel-forming core sequence (RADA) modified with SDKP motif with pro-angiogenic and anti-fibrotic activity to be used as a cardioprotective scaffold. The RADA-SDKP hydrogel was intramyocardially injected into the infarct border zone of a rat model of MI induced by left anterior descending artery (LAD) ligation as a cell-free or a cell-delivering scaffold for bone marrow mesenchymal stem cells (BM-MSCs). The left ventricular ejection fraction (LVEF) was markedly improved after transplantation of either free hydrogel or cell-laden hydrogel. This cardiac functional repair coincided very well with substantially lower fibrotic tissue formation, expanded microvasculature, and lower inflammatory response in the infarct area. Interestingly, BM-MSCs alone or in combination with hydrogel could not surpass the cardiac repair effects of the SDKP-modified SAP hydrogel. Taken together, we suggest that the RADA-SDKP hydrogel can be a promising cell-free construct that has the capability for functional restoration in the instances of acute myocardial infarction (AMI) that might minimize the safety concerns of cardiac cell therapy and facilitate clinical extrapolation.

Indexed as

AnimalsBiocompatible MaterialsBone Marrow CellsCell-Free SystemChick EmbryoHydrogelsInflammationMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMyocardial InfarctionMyocytes, CardiacNeovascularization, PhysiologicPeptidesRatsBiocompatible MaterialsHydrogelsPeptidesVascular Endothelial Growth Factor Acardiac cell therapymesenchymal stem cellsmyocardial infarctionself-assembling peptide hydrogel

Identifiers

PMID32019267
PMCPMC7072713
OpenAlexW3003796824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.